Form 4: Amphastar Pharmaceuticals Director Floyd F. Petersen Sells Shares Under 10b5-1 Plan

Floyd F. Petersen, a director at Amphastar Pharmaceuticals, sold a portion of his holdings under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 1, 2024, Floyd F. Petersen, a director of Amphastar Pharmaceuticals, sold 451 shares of common stock at a weighted average price of $45.6041.
• Additionally, Petersen sold 49 shares of common stock at a weighted average price of $46.5284 on the same day.
• These sales were executed under a Rule 10b5-1 trading plan adopted on June 13, 2023.
• Following these transactions, Petersen directly owns 79,833 shares of Amphastar Pharmaceuticals.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was conducted under a pre-arranged 10b5-1 trading plan, which mitigates concerns about insider selling based on current company performance.

Industry Context

Sales by company directors are a common occurrence and are often scrutinized by investors for insights into the director's perspective on the company's valuation and future prospects. Sales under a 10b5-1 plan are less likely to be indicative of the director's current sentiment, as these plans are pre-arranged.

Stakeholder Impact

• The sale of shares by a director could potentially create uncertainty among shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates